Journal article · 2022

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Emma J Searle, Hang Quach, Sandy Wai Kuan Wong, Luciano J. Costa, Cyrille Hulin, Wojciech Janowski, Jesús G. Berdeja, Sébastien Anguille, Jeffrey Matous, Cyrille Touzeau, Anne‐Sophie Michallet, Marla J. Husnik and 7 more

Blood, 140(Supplement 1), 394–396 · Published 15 November 2022 · DOI 10.1182/blood-2022-159711

View at the publisherCite this paper

In brief

“Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study” is a 2022 journal article by Emma J Searle and 18 co-authors, published in Blood. OpenAlex counts 65 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
65
Most cited in
2023 (23)
Authors
19

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Searle, E. J., Quach, H., Wong, S. W. K., Costa, L. J., Hulin, C., Janowski, W., Berdeja, J. G., Anguille, S., Matous, J., Touzeau, C., Michallet, A., Husnik, M. J., Vishwamitra, D., Niu, Z., Larsen, J. S., Chen, L., Goldberg, J. D., Popat, R., & Spencer, A. G. (2022). Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study. Blood, 140(Supplement 1), 394–396. https://doi.org/10.1182/blood-2022-159711

MLA 9

Searle, Emma J, et al. “Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study.” Blood, vol. 140, no. Supplement 1, 2022, pp. 394–396. https://doi.org/10.1182/blood-2022-159711.

Chicago

Searle, Emma J, Hang Quach, Sandy Wai Kuan Wong, Luciano J. Costa, Cyrille Hulin, Wojciech Janowski, Jesús G. Berdeja, et al. 2022. “Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study.” Blood 140 (Supplement 1): 394–396. https://doi.org/10.1182/blood-2022-159711.

Harvard

Searle, E. J. et al. (2022) ‘Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study’, Blood, 140(Supplement 1), pp. 394–396. doi:10.1182/blood-2022-159711.

IEEE

E. J. Searle et al., “Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study,” Blood, vol. 140, no. Supplement 1, pp. 394–396, 2022, doi: 10.1182/blood-2022-159711.

BibTeX

@article{searle2022teclistamab,
  title     = {{Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study}},
  author    = {Searle, Emma J and Quach, Hang and Wong, Sandy Wai Kuan and Costa, Luciano J. and Hulin, Cyrille and Janowski, Wojciech and Berdeja, Jesús G. and Anguille, Sébastien and Matous, Jeffrey and Touzeau, Cyrille and Michallet, Anne‐Sophie and Husnik, Marla J. and Vishwamitra, Deeksha and Niu, Zhuolu and Larsen, Julie S. and Chen, Ling‐Ling and Goldberg, Jenna D. and Popat, Rakesh and Spencer, Andrew G},
  journal   = {Blood},
  year      = {2022},
  volume    = {140},
  number    = {Supplement 1},
  pages     = {394--396},
  doi       = {10.1182/blood-2022-159711},
  url       = {https://doi.org/10.1182/blood-2022-159711}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201311
20232323
20242323
20251212
202655

Topic and keywords

Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments

  • teclistamab
  • multiple myeloma
  • daratumumab
  • lenalidomide
  • BCMA-CD3 bispecific antibody
  • combination therapy
  • cytokine release syndrome
  • immune effector cell-associated neurotoxicity syndrome

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Searle, E. J., Quach, H., Wong, S. W. K., Costa, L. J., Hulin, C., Janowski, W., Berdeja, J. G., Anguille, S., Matous, J., Touzeau, C., Michallet, A., Husnik, M. J., Vishwamitra, D., Niu, Z., Larsen, J. S., Chen, L., Goldberg, J. D., Popat, R., & Spencer, A. G. (2022). Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study. Blood, 140(Supplement 1), 394–396. https://doi.org/10.1182/blood-2022-159711

How many times has this paper been cited?

65 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Emma J Searle, Hang Quach, Sandy Wai Kuan Wong, Luciano J. Costa, Cyrille Hulin, Wojciech Janowski, Jesús G. Berdeja, Sébastien Anguille, Jeffrey Matous, Cyrille Touzeau, Anne‐Sophie Michallet, Marla J. Husnik and 7 more.

What is the DOI of this paper?

10.1182/blood-2022-159711, permanently at https://doi.org/10.1182/blood-2022-159711. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.